分享好友 环球市场首页 环球市场分类 切换频道

Preimplantation Genetic Testing Market

2025-02-1200

Market Overview

The Global Preimplantation Genetic Testing Market size is expected to be worth around USD 1648.6 Million by 2033 from USD 756.6 Million in 2023, growing at a CAGR of 8.1% during the forecast period from 2024 to 2033.

Preimplantation genetic testing, also referred to as preimplantation genetic diagnosis, involves screening embryos produced through in vitro fertilization for genetic abnormalities prior to being implanted into uteruses. Medical professionals perform this screening test so as to detect genetic flaws within embryos so as to implant only healthy ones into gestationsal sacs – with its primary goal being increasing likelihood of successful pregnancy while decreasing risks passed from parentage through inheritance of genetic conditions and passing them down through offspring.

Preimplantation involves different procedures including egg harvesting from either mother or donor eggs then followed by in vitre fertilization followed by in vitreation before final implantation occurs resulting in vitro fertilization followed by in vitreation with final resultant embryo resulting from fertilization followed by in vitre fertilization of resultant embryos during in utero.

Post-fertilization, eggs are subject to screening to detect genetic abnormalities. Viable embryos may be preserved through freezing while nonviable ones must be discarded; implanting healthy embryos is paramount in order to achieve successful pregnancy; preimplantation genetic testing also offers gender selection but this presents ethical concerns; nonetheless many individuals dealing with sexually linked genetic conditions, single gene donors with chromosomal problems seeking pregnancy as well as older women and those experiencing repeated abortions increasingly seek this therapeutic option for infertility issues are turning towards preimplantation genetic testing as a treatment option as an aid against infertility.

Preimplantation Genetic Testing Market Size

Key Takeaways

By Procedure Type

In 2023, Preimplantation Genetic Diagnosis held approximately 78% of market revenue share and projected to experience the fastest compound annual growth rate during its forecast period. This segment’s growth can be attributed to increasing awareness among healthcare professionals and consumers regarding genetic testing for specific gene mutations.

This segment’s growth has been propelled by an increased incidence of single gene diseases and translocation cases, coupled with market entities’ effective implementation of Next-Generation Sequencing (NGS) technology. Preimplantation Genetic Diagnosis (PGD) services play an essential role in screening embryos to detect specific gene mutations that contribute to decreased instances of genetic diseases in newborns.

Preimplantation Genetic Screening (PGS) services involve screening embryos for any chromosomal abnormalities. PGS screening services are recommended for couples of advanced reproductive age, multiple In Vitro Fertilization (IVF) cycles and repeated miscarriages, or those experiencing repeated pregnancy loss. Due to continually rising demand and advancements in IVF procedures, PGS services look set for lucrative growth in the forecast period. Furthermore, high capacity laboratories that conduct many IVF processes ensure superior PGS services further fueling this growth segment’s expansion.

By Product Type

In 2023, reagent & consumables represented 50.6% of revenue and were projected to experience the fastest compound annual growth rate through 2033. PGT’s rising adoption in In Vitro Fertilization (IVF) processes has driven its escalation, leading to over 2.7 million cycles per year and over 500,000 deliveries via IVF yearly – propelling demand for PGT-related consumables such as next-generation sequencing tests such as polymerase chain reaction or fluorescent in-situ hybridization which will continue its upward trajectory in growth over time.

Instruments held a second-largest share in the preimplantation genetic testing market in 2023, as market players continue to focus on developing advanced genetic testing instruments with accurate results. Furthermore, more hospitals and clinics offering IVF services is projected to drive demand for on-site preimplantation genetic testing of pregnancies requiring PGT services.

By Technology

Polymerase chain reaction (PCR) held the highest revenue share at 40.6% in 2023. This is attributable to its wide penetration, cost-effectiveness, and precision; all factors which contributed to its dominant market presence. PCR tests can generate multiple copies of specific genomic segments which increases chances of detecting chromosomal abnormalities within samples; furthermore its specificity and sensitivity make PCR an excellent method for various genetic diagnoses.

Next-Generation Sequencing (NGS) is projected to experience the fastest compound annual growth rate during its forecast period, thanks to its superior accuracy compared with other tests and ability to sequence large amounts of DNA rapidly. Technological advances have expanded NGS’ scope, enabling detection of additional chromosomal abnormalities.

By Application

Aneuploidy screening dominated the preimplantation genetic testing market in 2023, accounting for 26.8% of its revenue share, and is anticipated to show an unprecedented compound annual growth rate throughout its forecast period. Aneuploidy screening techniques are commonly used to evaluate embryo quality during In Vitro Fertilization (IVF). Their projected expansion can be attributed to the rising adoption of such techniques and innovative products entering the market.

HLA Typing was the second-highest market share holder in 2023. This was driven by preimplantation genetic testing, specifically embryo HLA typing for stem cell therapy; HLA typing provides crucial preimplantation genetic tests with higher survival rates compared to transplantation from unrelated donors; thus amplifying HLA testing’s importance in preimplantation genetic testing.

By End-User

The hospital segment accounted for the highest revenue share of around 40% in 2023. High patient inflow, improved healthcare infrastructure, and the presence of public and private hospitals offering IVF services are some of the major factors driving the segment’s growth. Mostly, couples who are seeking fertility treatment go to hospitals for further treatments, because of the highly advanced technology available at hospitals. In addition, the rise in research at hospitals is expected to increase testing rates in hospital settings. Moreover, the hospital segment is projected to experience the fastest growth in the coming years.

The fertility centers segment held the second-largest share of the preimplantation genetic testing industry in 2023. Improvement of healthcare infrastructure in fertility centers and technological advancements in testing services are expected to drive the growth of the segment in the forthcoming years.

Preimplantation Genetic Testing Market Share

Key Market Segments

Procedure Type

Product Type

Technology

Application

End-User

Drivers

Increased Adoption of Assisted Reproductive Technologies (ART)

Preimplantation Genetic Testing (PGT) market growth is being driven by increasing adoption of assisted reproductive technologies such as In Vitro Fertilization (IVF). With increasing numbers of individuals and couples turning to IVF for fertility solutions, PGT becomes an integral component in increasing its success rates; its ability to detect genetic abnormalities prior to implantation contributes significantly to better pregnancy outcomes.

Growing Awareness of and Innovations in Genetic Testing Technologies

Growing awareness among healthcare professionals and prospective parents about the benefits of genetic testing is driving its rise as an assessment tool. Technological advancements like Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Fluorescent In-Situ Hybridization (FISH), have enhanced accuracy and efficiency of PGT; becoming reliable methods of assessing embryo health. Trend: PGT adoption as reliable evaluation method has seen rapid increase over time.

Trend

An Aneuploidy Screening Boom and Expanded PGT Applications

One trend in the PGT market to watch out for is aneuploidy screening’s growing prevalence in IVF embryo quality evaluation, in line with increasing precision of fertility treatments. Furthermore, PGT applications are expanding beyond traditional genetic disorders to HLA typing for stem cell therapy to provide more holistic knowledge of embryonic health.

Integrating Artificial Intelligence (AI) Into Genetic Analysis

AI in genetic analysis represents a noteworthy trend. AI applications are now being employed to analyze vast datasets generated by genetic testing, making more precise and efficient identification of genetic abnormalities possible. Not only does this speed up analysis but it also aids with selecting healthy embryos for implantation more quickly. But this approach comes at a price there may be potential restrictions due to AI usage within genetic analysis itself.

Restraint

Ethical and Societal Concerns

Ethical and societal concerns surrounding genetic testing and manipulation of embryos present a major challenge to widespread adoption of PGT technologies. Concerns such as selecting specific traits for designer babies and disposing nonviable embryos generate controversy and often resist widespread implementation of these technologies.

Cost-Intensive Nature of PGT Procedures

Preimplantation Genetic Testing procedures can be prohibitively expensive, making them inaccessible for some individuals or couples. PGT involves advanced technologies and expertise which may incur higher expenses; thus limiting adoption in regions with limited financial resources or inadequate insurance coverage.

Opportunity

Expanding Applications of Personalized Medicine

One promising application of PGT lies in personalized medicine, with genetic testing technologies progressing and opening up opportunities for personalized treatments that match individual’s genetic makeup based on personalized healthcare interventions tailored specifically for them. PGT allows healthcare providers to identify genetic markers associated with diseases or conditions for more targeted care delivery.

Concentration on Male Infertility and Sperm Genetic Testing

There is an increasing opportunity in PGT’s landscape for male infertility and sperm genetic testing. While PGT traditionally focused on evaluating embryo genetic health, there has been increasing recognition of its value when applied to testing sperm quality and integrity – thus providing opportunities for creating advanced techniques to address male infertility comprehensively.

Regional Analysis

North America secured 36.4% market share and contributed USD 275.4 Million revenue to the global preimplantation genetics diagnosis (PGD) market in 2023, The rise of North America can be attributed to increasing healthcare expenditures coupled with an expanding population in this industry sector.

Massachusetts, Columbia and New Jersey stand out with high rates of births that resulted from assisted reproductive technology; this underlines their involvement and success with PGD solutions.

Preimplantation Genetic Testing Market Region

Key Regions and Countries

North America

Western Europe

Eastern Europe

APAC

Latin America

Middle East & Africa

Key Player Analysis

Industry players are taking steps to expand their presence across regional markets through various strategies, including the introduction of new products, acquisitions and collaborations. These endeavors should lead to improved product development capabilities, operational efficiencies and expanded market reach for those involved companies.

Key Market Players

Recent Developments

点赞 0
举报
收藏 0
评论 0
分享 0